Elilily击败了收入估算,提高了2025年的指导意见,增强了投资者的信心。 Eli Lilly beat earnings estimates and raised 2025 guidance, boosting investor confidence.

Elilly报告第二季度成绩强劲,每股收入6.31美元,超过估计数7.72美元,全年收入增长37.6%,达155.6亿美元。 Eli Lilly reported strong second-quarter results, with earnings of $6.31 per share, surpassing estimates by $0.72, and revenue rising 37.6% year-over-year to $15.56 billion. 该公司将其2025年全年收入指导提高到每股21.75至23.00美元,而分析师预测为23.48美元。 The company raised its full-year 2025 earnings guidance to $21.75–$23.00 per share, while analysts project $23.48. 机构投资者的股份增加,一些公司增加了股权,内部人购买的股份总额约为289万美元。 Institutional investors increased holdings, with several firms boosting stakes, and insiders purchased shares totaling about $2.89 million. 股票交易额为833.08美元,市场上限为7884.7亿美元,“多价购买”共识评级为948.56美元,平均价格目标为948.56美元。 The stock, trading at $833.08, has a market cap of $788.47 billion and a "Moderate Buy" consensus rating with a $948.56 average price target.